TY - JOUR
T1 - mRNA display selection of a high-affinity, Bcl-XL-specific binding peptide
AU - Matsumura, Nobutaka
AU - Tsuji, Toru
AU - Sumida, Takeshi
AU - Kokubo, Masahito
AU - Onimaru, Michiko
AU - Doi, Nobuhide
AU - Takashima, Hideaki
AU - Miyamoto-Sato, Etsuko
AU - Yanagawa, Hiroshi
PY - 2010/7
Y1 - 2010/7
N2 - Bcl-XL, an antiapoptotic member of the Bcl-2 family, is a mitochondrial protein that inhibits activation of Bax and Bak, which commit the cell to apoptosis, and it therefore represents a potential target for drug discovery. Peptides have potential as therapeutic molecules because they can be designed to engage a larger portion of the target protein with higher specificity. In the present study, we selected 16-mer peptides that interact with Bcl-XL from random and degenerate peptide libraries using mRNA display. The selected peptides have sequence similarity with the Bcl-2 family BH3 domains, and one of them has higher affinity (IC50=0.9 μM) than Bak BH3 (IC50=11.8 μM) for Bcl-XL in vitro. We also found that GFP fusions of the selected peptides specifically interact with Bcl-XL, localize in mitochondria, and induce cell death. Further, a chimeric molecule, in which the BH3 domain of Bak protein was replaced with a selected peptide, retained the ability to bind specifically to Bcl-X L. These results demonstrate that this selected peptide specifically antagonizes the function of Bcl-XL and overcomes the effects of Bcl-XL in intact cells. We suggest that mRNA display is a powerful technique to identify peptide inhibitors with high affinity and specificity for disease-related proteins.
AB - Bcl-XL, an antiapoptotic member of the Bcl-2 family, is a mitochondrial protein that inhibits activation of Bax and Bak, which commit the cell to apoptosis, and it therefore represents a potential target for drug discovery. Peptides have potential as therapeutic molecules because they can be designed to engage a larger portion of the target protein with higher specificity. In the present study, we selected 16-mer peptides that interact with Bcl-XL from random and degenerate peptide libraries using mRNA display. The selected peptides have sequence similarity with the Bcl-2 family BH3 domains, and one of them has higher affinity (IC50=0.9 μM) than Bak BH3 (IC50=11.8 μM) for Bcl-XL in vitro. We also found that GFP fusions of the selected peptides specifically interact with Bcl-XL, localize in mitochondria, and induce cell death. Further, a chimeric molecule, in which the BH3 domain of Bak protein was replaced with a selected peptide, retained the ability to bind specifically to Bcl-X L. These results demonstrate that this selected peptide specifically antagonizes the function of Bcl-XL and overcomes the effects of Bcl-XL in intact cells. We suggest that mRNA display is a powerful technique to identify peptide inhibitors with high affinity and specificity for disease-related proteins.
KW - BH3 domain
KW - Bcl-2 family
KW - Therapeutic peptide
UR - http://www.scopus.com/inward/record.url?scp=77954440172&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77954440172&partnerID=8YFLogxK
U2 - 10.1096/fj.09-143008
DO - 10.1096/fj.09-143008
M3 - Article
C2 - 20181936
AN - SCOPUS:77954440172
SN - 0892-6638
VL - 24
SP - 2201
EP - 2210
JO - FASEB Journal
JF - FASEB Journal
IS - 7
ER -